Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) announced the appointment of Dr. Vijay Iyengar to its Board of Directors, effective September 9, 2026. The company also increased the size of its board from nine to ten directors to accommodate the new member.
Dr. Iyengar, age 54, has been appointed as a Class III director, with a term that will expire at the company’s 2029 annual meeting of stockholders, subject to earlier resignation, death, or removal. The company stated he is qualified to serve due to his extensive background in the life sciences industry.
Dr. Iyengar previously served as Executive Vice President, Global Medical Affairs, Product and Partnership Strategy at Incyte Corporation from May 2022 to November 2025. Prior to that, he was Executive Vice President, Global Strategy and Corporate Development at Incyte from May 2016 to April 2022. Earlier in his career, he held leadership roles at Novartis, including President of Genoptix Medical Laboratory and Vice President of the Rare Diseases Franchise Head at Novartis Oncology. He holds a B.S. in Biology from Stanford University and an M.D. from Harvard Medical School.
As a non-employee director, Dr. Iyengar will receive a base annual retainer of $40,000 under the company’s Outside Director Compensation Policy. On September 9, 2026, he was granted an initial award of stock options to purchase 76,080 shares of the company’s common stock. This award will vest on a monthly basis over three years, subject to his continued service through the applicable vesting dates.
The company noted that there are no family relationships between Dr. Iyengar and any current director or executive officer, and he was not selected by the Board pursuant to any arrangement or understanding with any person.
